Diacomit

Diacomit ^®contains 250 mg stiripentol^[1]^[2]

In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union Dravet's syndrome does not exist data for combined therapy both valproic acid or clobazam^[4]

ATC

http://www.whocc.no/atc_ddd_index/?code=N03AX17

References

References:

↑ http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf
↑ A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984; 34(2):199-204.
↑ Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABA_A-Receptor Channels
↑ Aras et al 2015

[1] ttp://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf

[2] A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984; 34(2):199-204.

[3] Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABA_A-Receptor Channels

[4] Aras et al 2015

[1]

[2]

[3]

[4]

Diacomit

ATC

References

Navigation menu

Search